bioAffinity Technologies, Inc. is a biotechnology company. The Company is focused on addressing the need for noninvasive diagnosis of early-stage cancer and diseases of the lung, as well as a targeted cancer treatment. The Company develops noninvasive diagnostic tests and cancer therapeutics using technology that preferentially targets cancer cells and cell populations indicative of a diseased state. Its lead product, CyPath Lung, addresses the need for noninvasive detection of early-stage lung cancer. Through its wholly owned subsidiary, OncoSelect Therapeutics, LLC, the Company’s research is engaged in the discoveries and advancement of cancer therapeutics that specifically and selectively target cancer cells. It is focused on expanding its platform technologies in developing tests that detect and therapies that target various types of cancer and potentially other diseases.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Annual Dividend Rate
Price/Cash Flow (TTM)